Share this video  

ASCO 2023 | Validating MIA & MSKCC predictive tool for melanoma sentinel node status

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, compared the predictive models developed by the Memorial Sloan Kettering Cancer Center (MSKCC) and Melanoma Institute Australia (MIA) for determining sentinel lymph node (SLN) status in patients with melanoma. The study included 10,089 patients who underwent SLN biopsy. Both models demonstrated good calibration and similar accuracy. However, decision curve analysis (DCA) showed that using the models improved SLN selection only when a risk threshold of at least 10% was used, particularly for T2 melanomas. Further development of the nomograms or alternative strategies are needed to enhance selection at lower risk thresholds. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.